Testing NovoTTF device use in routine treatment for pleural mesothelioma
Part of Cancer, Lungs & breathing clinical trials.
This trial studies using the NovoTTF-200T device as part of regular care for people with pleural mesothelioma when surgery that could cure the cancer isn’t an option. It may help doctors understand how well this device fits into real-world treatment and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have pleural mesothelioma confirmed by biopsy (tissue test)
- Your cancer can’t be cured with surgery (resection isn’t an option)
- Your care team plans to use the NovoTTF-200T device as recommended by the instructions and medical guidelines
- You are expected to live more than 3 months
- You agree to sign consent for using and processing your study data
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial tests a device that sends low-energy electrical fields (called Tumor Treating Fields) to the lung tumor before surgery. The goal is to see if it can help shrink the tumor and improve surgical outcomes.
This trial tests a wearable device that puts low-intensity electric fields on the skin over spinal tumors to slow their growth. It's for people whose spinal metastases have already been treated with surgery and/or radiation and have no more radiation options.
This trial tests a new type of immune cell therapy made from donor cells that are trained to target two specific proteins found on mesothelioma tumors. The goal is to see if these cells can safely shrink tumors or slow the disease when given directly into the chest or belly area.
This Phase 2 study tests whether adding nivolumab (an immunotherapy) to a one-time “light-based” treatment during a lung procedure can control malignant pleural mesothelioma that can’t be surgically removed. You may be eligible if your cancer has come back or progressed after prior platinum chemotherapy, and if your tumor is reachable for the light treatment during thoracoscopy.
Hear when a new Pleural Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.